Cytori Therapeutics Inc (NASDAQ:CYTX) shares shot up 12.1% during mid-day trading on Friday . The stock traded as high as $0.37 and last traded at $0.37. 850,803 shares were traded during trading, an increase of 6% from the average session volume of 805,119 shares. The stock had previously closed at $0.33.

Several research firms recently issued reports on CYTX. ValuEngine raised shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. Zacks Investment Research cut shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Maxim Group set a $10.00 price target on shares of Cytori Therapeutics and gave the stock a “buy” rating in a report on Monday, July 10th. Finally, B. Riley reissued a “buy” rating and set a $2.30 price target on shares of Cytori Therapeutics in a report on Monday, May 15th.

The stock’s market capitalization is $12.84 million. The stock has a 50-day moving average of $0.41 and a 200-day moving average of $1.03.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.23 million. During the same quarter last year, the firm posted ($0.43) earnings per share. The firm’s quarterly revenue was down 18.2% compared to the same quarter last year. Equities analysts predict that Cytori Therapeutics Inc will post ($0.60) EPS for the current fiscal year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. increased its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 612,304 shares of the biotechnology company’s stock after purchasing an additional 275,653 shares during the quarter. Vanguard Group Inc. owned 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.82% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.